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Plasma and muscle free amino acids during continuous
ambulatory peritoneal dialysis
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Plasma and muscle free amino acids during continuous ambulatory
peritoneal dialysis. Free amino acids (AA) were determined in plasma
and in muscle tissue of 29 patients undergoing continuous ambulatory
peritoneal dialysis (CAPD) for 2 to 38 months. Muscle biopsies were
taken in the morning after an overnight dwell with 1.36% glucose
dialysis fluid. Muscle intracellular water was calculated using the
chloride method. The intracellular (ic) and extracellular (cc) concentra-
tion and the ic/cc gradient for each AA was calculated and compared
with values in matched healthy controls. Most of the essential and
several non-essential AA were low in plasma. By contrast, none of the
essential AA were low in muscle, and methionine was increased as were
ornithine, asparagine, and aspartic acid; however, muscle taurine was
markedly reduced. The ic/cc gradient was increased for most essential
and several non-essential AA. In plasma, taurine precursors, methio-
nine and cysteine, were not reduced and the ratios taurine/cysteine and
taurine/methionine were low. Muscle taurine/methionine was also low.
Thus, during CAPD muscle free AA are, in general, well maintained,
suggesting that marked reductions of plasma AA levels in CAPD
patients may reflect an cc to ic shift rather than depletion. The finding
of low muscle taurine, but normal or increased cysteine and methionine
pools, suggests that taurine depletion during CAPD is caused by
blocked synthesis or low intake of taurine.
Chronic renal failure is associated with various plasma and
muscle free amino acid abnormalities, some of which are
thought to be due to uremia per se or due to impaired renal
degradation or excretion in the urine, whereas others may
reflect inadequate nutritional intake and malnutrition [1—4].
Amino acid alterations persist in uremic patients despite hemo-
dialysis or intermittent peritoneal dialysis and the free amino
acid pools are not fully normalized by supplementation of
essential amino acids in conventional proportions [1—5].
Continuous ambulatory peritoneal dialysis (CAPD) involves
several factors that may further aggravate the abnormal metab-
olism of amino acids in uremia: loss of amino acids and proteins
into the dialysate, increased protein catabolism during episodes
of peritonitis, and loss of appetite and declining dietary protein
intake over time on the treatment [6—101. Since deficient free
amino acid pools may limit protein synthesis, and may thus
contribute to malnutrition in patients undergoing CAPD [10—
13], it is of interest to investigate the free amino acid status in
CAPD patients. Previous studies from us [14—16] and others [6—
8, 17—191 have shown profound plasma amino acid alterations,
whereas in another study [91 a less abnormal pattern was found.
However, the clinical significance of these findings is unclear.
Plasma amino acid levels are rapidly changed by factors such as
stress, infections, and day-to-day variations of protein and
energy intake, and they may therefore be less suitable as
indicators of the chronic nutritional status [2, 4, 20]. Moreover,
the fact that CAPD patients are continuously exposed to
glucose absorption from the dialysate and are never in a
completely fasted state, may further complicate the interpreta-
tion of plasma amino acid data in this group of patients.
A more specific, and a partly different uremic amino acid
pattern is found intracellularly in skeletal muscle, which con-
tains the largest pool of free amino acids in the body [1, 3, 5,
21]. Muscle free amino acids are thought to be more suitable as
indicators of the chronic nutritional status in uremic patients [1,
3, 5, 21]. In a preliminary study, we found low muscle free
taurine and tyrosine levels in patients undergoing CAPD but
otherwise normal or increased intracellular free amino acid
concentrations; by contrast, plasma aminograms in the same
patients showed gross abnormalities with marked reductions of
most of the essential amino acids [16]. Graziani et al [19] also
found significantly reduced muscle free tyrosine levels in their
CAPD patients as well as low intracellular concentrations of
valine and leucirie.
The present study was designed to evaluate the plasma and
muscle free amino acid status of patients undergoing CAPD, to
examine the relationship between extracellular and intracellular
free amino acid concentrations, and to study the effect of the
treatment duration on these variables. For this purpose, plasma
and muscle free amino acids were determined in 29 CAPD
patients after 2 to 38 months' treatment while the patients were
eating their usual diets.
Methods
Patients
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Twenty-nine uremic patients were studied after a mean of
nine months' treatment with CAPD. Patients with diabetes
mellitus or other systemic disease, or active liver disease were
excluded. All patients had been treated with low protein diets
for periods ranging from one month to several years before
starting any form of dialysis. Each patient received intermittent
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Table 1. Characteristics of patients undergoing CAPD
CAPD
Controls patients
N=21 N=29
Sex female/male 5/16 7/22
Age years 55 15 56 12
Heightcm 175±6 173
Body weight kg
Broca's indexa
73 12
0.98 0.10
65 10b
0.90 O.l2'
Duration of CAPD months — 9 10
Serum urea mmol/liter — 22 6
Serum creatinine — 986 264
i.mol/liter
Serum albumin g/liter — 36 4
Serum total protein g/liter — 64 7
Values are means SD.
a Body weight (kg)/height (cm) —100
b P < 0.05
peritoneal dialysis for one week to three months (mean, one
month) before starting on CAPD, and six patients had previ-
ously been treated with hemodialysis for periods ranging from
one month to eight years. The total duration of all previous
treatment including CAPD was, on the average, 19 months
(range, 3 to 105 months) at the time of the muscle biopsy study.
The mean (± SD) per cent ideal body weight (based upon
medium framed individuals, Metropolitan Life Insurance Ta-
bles, 1959) of the patients was 99.6 12.4%. Clinical charac-
teristics of the patients are given in Table 1.
Dialysis technique
CAPD was performed with four to five daily exchanges of
two liters of dialysis fluid (Dianeal®, Baxter-Travenol, Deer-
field, Illinois, USA, or Halden, Norway) containing (in mmol/
liter) sodium 132, calcium 1.75, magnesium 0.75, chloride 102,
and lactate 35, and anhydrous dextrose either 13.6, 22.7, or 38.6
glliter. The patients used the different glucose concentrations
according to their need to remove excess fluid.
Drugs
All patients received a daily vitamin supplement which
contained B vitamins and ascorbic acid. Several patients con-
sumed furosemide, beta-blockers, aluminum hydroxide, cal-
cium carbonate, sodium bicarbonate, folic acid, and vitamin D.
None of the patients received androgenic steroids, insulin, oral
hypoglycemic drugs, oral contraceptives, or lipid-lowering
agents.
Diet
The patients were prescribed a dietary protein intake of at
least 1.2 g proteinlkg/day. mainly of high biological value, and a
dietary energy intake of at least 35 kcallkg/day. Data obtained
during 18 metabolic studies in nine CAPD patients, eight of
whom are included in the present study, after a mean of eight
months on CAPD showed that actual dietary protein and energy
intakes were, respectively, 1.4 0.3 g protein/kg/day and 32
6 kcallkg/day [22]. In addition, 7 2 kcal/kglday were derived
from peritoneal absorption of glucose. Protein, fat, and carbo-
hydrates averaged 14 3%, 32 6%, and 54 5% of the total
energy intake [22].
Living habits
Fifteen of the patients were working full time (10 patients) or
part time (5 patients), and all except two patients were able to
manage housework. The degree of physical activity was gener-
ally low: none of the patients were practicing endurance exer-
cise training. Five of the patients were cigarette smokers.
Alcohol consumption was generally low or absent.
Control subjects
Healthy control subjects were recruited either from the
hospital staff or from a group of healthy elderly men and
women. Data from these two groups of healthy volunteers,
showing important age- and sex-related differences in plasma
and muscle free amino acid patterns, have been reported earlier
[1, 3, 23, 24]. Twenty-one of these healthy volunteers were
selected in the present study to match the patients as regards
sex, age, and height (Table 1). Body weight and Broca's
weight-to-height index were lower in the patients than in the
controls. It should be noted that living habits and nutritional
intakes differed between patients and control subjects. Also,
the fasting conditions prior to the muscle biopsy investigation
differed since the patients were exposed to glucose absorption
from the dialysate.
Protocol
Muscle biopsy and venous blood samples were taken from
each patient and control subject after an overnight (10 to 14
hours) fast. Each patient used dialysis fluid containing 13.6 g
glucose/liter during the night before the investigation and the
dialysate was not exchanged until after the investigation. The
overnight dwell lasted for, on the average, 10 hours. Medica-
tions were omitted on the morning of the study. None of the
patients had had peritonitis within one month before the study.
Informed consent was obtained from each patient and control
subject. The study protocol was approved by the Ethics Com-
mittee of Karolinska Institute.
Muscle biopsy and analytical methods
Muscle tissue was obtained by percutaneous needle biopsy
from the lateral part of the quadriceps femoris muscle as
described earlier [25]. All visible fat and connective tissue were
rapidly removed from the biopsy material which was then
divided into several portions. One to three pieces (10 to 20 mg
each) were used for determinations of muscle fat, water, and
chloride as described earlier [25—28]. One to three pieces (6 to
31 mg each) were homogenized and used for duplicate or
triplicate determinations of muscle free amino acids. Blood
samples were centrifugated at 4000 rpm for 10 minutes to obtain
blood plasma. Muscle and plasma samples were deproteinized
with sulphosalicylic acid, centrifuged, and the supernatants
were stored at —70°C until analyzed. Muscle and plasma free
amino acids were analyzed with automatic ion-exchange chro-
matography (Labotron CHR-2 or Liquimat III, Kontron, Swit-
zerland, or amino acid analyzer 4400 or 4151 Alpha Plus, LKB
Biochrom Ltd, Cambridge, UK) using a lithium buffer system
with five picobuffers and an internal standard (norleucine) as
described earlier [3, 26]. Serum albumin, total proteins, chlo-
ride, urea, and creatinine were measured by routine methods.
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Table 2. Muscle intracellular free amino acid concentrations and plasma free amino acid concentrations in CAPD patients and control subjects
Muscie free amino acids smol/liter intracellular water Plasma free amino acids .tmol/liter plasma water
(N) Controls (N) CAPD(N) Controls (N) CAPD
Essential
Histidine (21) 598 230 (29) 537 150 (21) 109 29 (28) 75 18"
Isoleucine (20) 109 39 (25) 162 92 (21) 70 17 (29) 61 19
Leucine (21) 233 120 (26) 239 99 (21) 151 25 (29) 100 26b
Lysine (21) 1322 379 (29) 1499 510 (21) 216 45 (28) 154 39'
Methionine (19) 47 29 (13) 105 55 (21) 29 7 (29) 28 9
Phenylalanine
Threonine
(21)
(21)
79 40
906 204
(23)
(29)
101 43
800 208
(21)
(21)
66 14
171 48
(29)
(29)
60 15
117 43i
Tyrosine (20) 123 85 (24) 104 40 (21) 94 26 (29) 52 20b
Valine (21) 365 112 (29) 312 123 (21) 278 66 (29) 175 48b
Non-essential
Alanine (21) 3278 1051 (29) 3519 1344 (21) 400 91 (29) 378 107
Arginine (21) 946 714 (28) 891 447 (21) 98 49 (29) 81 33
Asparagine
Aspartic acid
(21)
(21)
413 202
2041 606
(14)
(29)
993 573b
2589 668
(20)
(21)
59 17
11 5
(26)
(29)
76 29
20 10b
Citrulline (19) 224 162 (27) 325 220 (20) 49 17 (26) 98 38"
Cysteine ( ) ( ) (21) 68 14 (27) 64 17
Glutamic acid (21) 4693 1312 (28) 5105 1058 (20) 43 19 (27) 72 39
Glutamine (21) 22308 6454 (29) 20733 4656 (21) 775 201 (28) 514 129"
Glycine (21) 2171 861 (21) 2048 652 (21) 300 120 (29) 278 Ill
Ornithine (21) 480 191 (21) 650 235 (21) 112 32 (28) 79 36
Proline (21) 1313 716 (21) 1699 698 (20) 246 128 (23) 304 116
Serine (21) 1191 401 (21) 1003 391 (20) 155 48 (29) 73 17k'
Taunne (21) 19461 6342 (21) 12631 5310b (20) 104 50 (29) 69 28b
1-methylhistidine
3-methylhistidine
( ')( ) ( )(20) 138 129!' (II)(21) 12 75 2 (20)(28) 37 20"42 11"
Ratios
Valine/glycine
Glycine/serine
Tyrosine/phenylalanine
Taurine/methionine
(21)
(21)
(20)
(19)
0.19 0.09
1.91 0.73
1.47 0.69
601 440
(29)
(29)
(23)
(13)
0.17 0.11
2.21 0.79
1.19 0.87
133 88"
(21)
(20)
(21)
(20)
1.02 0.34
1.96 0.46
1.44 0.25
3.59 1.15
(29)
(29)
(29)
(29)
0.72 0.3la
3.93 1,79b
0.85 0.20"
2.60 100b
Taurine/cysteine ( ') ( k) (20) 1.51 0.67 (27) 1.07 0.39
Values are mean SD. Histidine and tyrosine are regarded as essential amino acids in uremia [1—3]. (*) Not detected.
a p < 0.01; b P < 0.001
Calculations
The methods used for determination of the muscle contents
of water, electrolytes, and free amino acids and the methods for
calculation of the muscle intracellular water content and muscle
intracellular free amino acid concentrations have been de-
scribed earlier [25—27]. In short, the muscle content of extra-
cellular and intracellular water was calculated according to the
chloride tnethod, assuming the resting membrane potential of
muscle to be —87.2 mV. Since chloride is freely diffusible
across the cell membrane and is distributed according to
Nernst's equation, the ratio between the extracellular and
intracellular chloride concentrations is 26: 1. Muscle free intra-
cellular amino acid concentrations were calculated by subtract-
ing the free extracellular part from the total muscle content,
assuming that the concentrations in the interstitial fluid were
equal to the plasma concentrations, and dividing by the calcu-
lated intracellular water content. The consequences of using a
reduced muscle membrane potential—which has been reported
to be characteristic for uremic patients [29]—for the calculation
of muscle intracellular water and solute contents have been
discussed earlier [27, 28].
Statistical methods
Computations were run on a PDP 11/24 computer at the
Department of Renal Medicine, Huddinge University Hospital,
with the program "Statpac." Statistical analyses included least-
square linear regression and Student's 1-test, and, when com-
paring mean values with different variances, the Behrens-Fisher
test with Cochran's modification. In the evaluation of plasma
and muscle free amino acids, statistical significahce was ac-
cepted only if P < 0.01. The 1% significance level wIts chosen
to take into account that a large number of variables (that is, 24
amino acids) are being compared. Otherwise (clinical charac-
teristics, Table 2), statistical significance was accepted at P <
0.05. Data are expressed as means SD.
Results
The mean values (±SD) of muscle free amino acids, ex-
pressed per liter of intracellular water, and plasma free amino
acids, expressed per liter of plasma water, in 29 CAPD patients
and in 21 age-, sex-, and height-matched healthy control sub-
jects are presented in Table 2. The plasma concentrations of
most of the essential and several non-essential amino acids
were significantly lower than in the controls. By contrast, the
mean muscle intracellular free amino acid concentrations of
most of the essential amino acids did not differ significantly
from values in the controls. Muscle methionine was in fact
significantly increased, and lysine, isoleucine, and phenylala-
nine also tended to be high whereas muscle tyrosine, valine,
threonine, and histidine showed borderline low values. Among
1222 Lindholm et a!: Muscle intracellular amino acids during CAPD
the non-essential amino acids, muscle ornithine, asparagine,
and aspartic acid showed significantly increased intracellular
concentrations whereas muscle taurine was markedly reduced,
to 65 27% of the normal mean value (Table 2).
The following essential amino acids had significantly reduced
mean plasma concentrations (expressed as the mean percentage
of the normal mean value): tyrosine (55 2 1%), valine (63
17%), leucine (66 17%), threonine (68 25%), histidine (69
17%), and lysine (71 18%). Isoleucine, phenylalanine, and
methionine also tended to be low (Table 2). Among the non-
essential amino acids, the mean plasma serine (47 11%),
glutamine (66 17%), taurine (66 27%), and ornithine (71
32%) levels were also significantly decreased compared with the
corresponding values in the control subjects. Several non-
essential amino acids including glutamic acid, aspttrtic acid,
citrulline, and 1- and 3-methyihistidine showed elevated plasma
levels and plasma proline and asparagine also tended to be high
(Table 2).
In Figures 1 and 2, the plasma and muscle free amino acid
concentrations and the intracellular to extracellular (ic/ec)
gradients for individual amino acids in the patients are ex-
pressed as a mean percentage (± SD) of corresponding mean
values in the control subjects. The mean ic/cc gradients for all
of the essential amino acids (except tryptophan which was not
measured in the present study) tended to be higher in the CAPD
patients than in the control subjects; the ic/cc gradient was
significantly increased for valine, leucine, histidine, lysine, and
isoleucine (Fig. 1). Among the non-essential amino acids, the id
cc gradient was significantly increased for serine, glutamine,
ornithine, and asparagine (Fig. 2).
As can be inferred from Table 2, the ic/cc gradient was about
2:1 to 15:1 for all of the essential amino acids and most of the
non-essential amino acids, whereas it was about 200: 1 for
aspartic acid and taurine. The ic/cc gradient for glutamic acid
and glutamine formed an intermediary group (Table 2).
The ratio of valine-to-glycine, tyrosine-to-phenylalanine, tau-
rine-to-methionine, and taurine-to-cysteine in plasma were sig-
nificantly reduced and the ratio of glycine-to-serine in plasma
was increased (Table 2). In muscle, the ratio of taurine-
to-methionine was markedly reduced to, on the average, 22
15% of the normal mean value.
Significant correlations between extracellular and intracellu-
lar amino acid concentrations were found only for taurine (r =
0.50, N = 29, P < 0.01), proline (r = 0.59, N 22, P < 0.01),
and 3-methylhistidine (r = 0.64, N = 28, P < 0.001). The
relationship between intracellular and extracellular concentra-
tions for taurine is shown in Figure 3. There were no statisti-
cally significant correlations between the duration of CAPD and
plasma amino acid concentrations. Nor did the muscle intracel-
lular amino acid concentrations correlate with the duration of
CAPD; however, muscle taurine tended to decrease with time
on CAPD (r =
—0.35, N = 29, P = 0.06).
Discussion
The results of this study show that during CAPD the plasma
free amino acid pattern is grossly abnormal, the predominant
alterations being marked reductions of most of the essential and
several of the non-essential amino acids. By contrast, the
muscle free amino acids were, in general, well maintained;
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Fig. 1. Essential muscle and plasma free amino acids and the gradient
between the muscle intracellular and extracellular concentration in 29
CAPD patients, expressed as the mean percentage (± SD) ofthe normal
mean value. The amino acids are ranked according to their deviations
from normal in plasma. Significant differences between patients and
control subjects are marked: * = P < 0.01, and ** = P < 0.001.
however, taurine was markedly reduced, to only 65 27% of
normal.
The finding of significantly reduced plasma tyrosine, valine,
leucine, threonine, histidine, and lysine levels in the CAPD
patients but normal plasma concentrations of isoleucine, phe-
nylalanine, and methionine, and low serine, glutamine, and
taurine levels are in general agreement with several previous
studies in CAPD patients [6—8, 17—19, 30]. However, there are
some discrepancies. For example, Kopple et al [9] found a less
abnormal amino acid pattern in nine CAPD patients; although
plasma leucine, valine and serine levels were found to be low,
the sum of the essential amino acids was not different from
normal. A low plasma histidine level in CAPD has previously
been reported in only one study in female CAPD patients [8],
whereas the present observation of a low plasma ornithine level
has not been reported previously in patients undergoing CAPD.
In general, the plasma free amino acid levels appear to be lower
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Gradient
Fig. 2. Non-essential muscle and plasma free amino acids and the
gradient between the muscle intracellular and extracellular concentra-
tion in 29 CAPD patients, expressed as the mean percentage (± so) of
the normal mean value. The amino acids are ranked according to their
deviations from normal in plasma. Significant differences between
patients and control subjects are marked: * = P < 0.01, and ** P <
0.001.
in the CAPD patients than in uremic patients undergoing other
forms of therapy [3, 4].
The reported average losses of free amino acids into the
dialysate during CAPD vary between 1.2 and 3.4 g/24 hours and
are thought to contribute but little to lower the plasma free
amino acid concentrations [6—10, 17]. Although the patients'
body weight and serum albumin levels were, on the average,
slightly lower than the controls', their mean percent ideal body
weight was close to 100%, indicating that the patients were not
severely malnourished. This suggests that the low plasma
amino acid levels may not necessarily reflect malnutrition and
amino acid depletion.
Although measures were taken to minimize the possible
effects of peritoneal glucose absorption during the hours pre-
ceding the tests, without interfering with the usual dialysis
regimen (Methods), the patients were, strictly speaking, not in a
completely fasted state. Thus, during an overnight dwell of 10
to 14 hours with 1.36% glucose dialysis fluid, about 4 to 8 g of
glucose are absorbed during the last four to eight hours of the
exchange (unpublished observation). It cannot be ruled out that
this might affect the plasma and muscle free amino acid levels.
However, the study of Kopple et al [9] may support the
supposition that plasma amino acid levels are not significantly
1'
20 40 60 80 100 120 140
Plasma free taurine, gmol/liter plasma water
Fig. 3. Relationship between the plasma free taurine and the muscle
free intracellular taurine concentration in 29 CAPD patients. The line
represents the regression line (y = 96.7X + 5940; r = 0.50; P < 0.01.
altered by the influence of the small amounts of glucose
remaining in the dialysate after art overnight dwell with 1.36%
glucose dialysis fluid.
The finding of a conspicuous difference between the plasma
and muscle free amino acid patterns, and the present observa-
tion that the ic/ec gradient was increased for most essential and
several non-essential amino acids, suggest that the observed
decrease in plasma amino acid levels may not reflect amino acid
depletion, but rather a shift of free amino acids from the
extracellular to the intracellular space. This could be a conse-
quence of hyperinsulinemia which typically occurs in renal
failure [31], and, in CAPD, the continuous absorption of glu-
cose stimulates insulin secretion further [32, 33]. Although
uremia is characterized by insulin resistance with respect to
glucose metabolism, and by compensatory hyperinsulinemia
[31], insulin resistance in uremia does not extend to the stimu-
lating effect of the hormone on cellular amino acid uptake [34].
Increased insulin-mediated transport of amino acids may there-
fore have contributed to low plasma amino acid levels and thus,
in the presence of well maintained muscle free intracellular
concentrations, to increased ic/cc gradients.
The muscle intracellUlar tyrosine, valine, threonine, and
histidine concentrations all tended to be low but none of these
amino acids was significantly changed compared with the
controls. Muscle valine has been found to be markedly reduced
in untreated uremic patients [3]; the results of the present study
suggest that this feature of uremia is relatively well controlled in
patients undergoing CAPD. On the other hand, Graziani et al
[19] found low muscle valine, and also low tyrosine, leucine,
phenylalanine, and serine concentrations in their CAPD pa-
tients. In a preliminary study, we found muscle tyrosine to be
significantly decreased in CAPD patients [16]. However, this
finding could not be confirmed in the present, extended study
using a more carefully matched control group. The present
results are quite similar to those reported by Metcoff et al [35]
for cellular amino acids in the circulating polymorphonuclear
cell in patients undergoing CAPD. In their patients, the intra-
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cellular concentrations were either normal or increased, while
most of the essential amino acids were low in plasma [35].
Significant correlations between the extracellular and the
intracellular concentrations were not found for any of the
essential and for only three of the non-essential amino acids
(taurine, proline, 3-methylhistidine). This is in agreement with
previous studies in uremic patients showing that plasma free
amino acid levels are poor indicators of the muscle free intra-
cellular amino acid status [1, 3, 5, 211.
The findings of the present study of increased plasma con-
centrations of the non-essential amino acids glutamic acid,
aspartic acid, citrulline, and 1-, and 3-methylhistidine are in
general agreement with previous studies in untreated uremic
patients or uremic patients undergoing CAPD or other forms of
therapy [1—3, 6—9, 17—19].
Patients with renal failure typically have reduced ratios of
plasma valine/glycine (commonly interpreted as an indicator of
malnutrition), low tyrosine/phenylalanine (reflecting impaired
hydroxylation of phenylalanine to form tyrosine), and increased
glycine/serine ratio (reflecting decreased conversion of glycine
to serine in the presence of normal or increased plasma glycine
levels in malnourished patients) [2]. The present study shows
that these abnormalities persist in patients undergoing CAPD,
whereas no significant alterations in the corresponding ratios
for intracellular free amino acids were observed.
Low plasma taurine levels in CAPD have previously been
reported by two other groups [6, 18], whereas plasma taurine
was found to be increased by Kopple et al [9]. In the present
study, plasma taurine in the healthy subjects was found to be
high compared with values reported by others [36, 37]. Since
contamination of plasma with platelets may result in increased
plasma taurine concentration [36, 37], this difference might be
due to different centrifugation procedures. However, plasma
from the CAPD patients and control subjects were handled
similarly, and it is therefore not likely that taurine release from
the platelets during the centrifugation procedure contributed to
the difference in plasma taurine concentrations between the
controls and CAPD patients.
The present finding that patients undergoing CAPD may
develop taurine deficiency is supported by the observation that
the intracellular taurine concentration tended to fall with time
on CAPD. Low muscle taurine has been observed also in
uremic patients undergoing treatment with low protein diets
supplemented with essential amino acids and in chronic hemo-
dialysis patients [3, 21, 38, 39]. Plasma taurine represents only
a minor fraction of the total pool of the free taurine in the body;
however, the correlation between extracellular and intracellular
taurine levels (Fig. 3) indicates that the intracellular taurine
pooi may be roughly estimated from measurements of plasma
taurine. The ic/ec gradient for taurine (Fig. 2) did not differ
between the patients and the controls (ic/cc gradient: 199 73
in the patients and 213 88 in the controls, NS). Thus, the low
intracellular taunne concentration is not likely to be caused by
any uremia-related transport phenomena.
The present observation of deficient free taurine pools de-
spite normal plasma cysteine and methionine levels, and intra-
cellular methionine being even increased, that is, precursor
sulphuric amino acids were not deficient, suggests that taurine
depletion during CAPD may be caused by blocked synthesis or
low exogenous supply of taurine. This is supported by the
finding of a significantly reduced taunne/methionine ratio in
muscle, and low taurine/methionine and taurine/cysteine ratios
in plasma. The recent observation of low taurine concentrations
in CAPD patients in the presence of high levels of cysteinesul-
finic acid, an intermediate metabolite in taunne synthesis,
suggests that impaired activity of cysteinesulfinic acid decar-
boxylase, possibly due to pyridoxine deficiency [40, 41], may
limit taurine synthesis [39, 42]. Our patients were prescribed 2
to 6 mg/day of supplemental pyridoxine hydrochloride (mean 4
mg/day) which may be too low to prevent deficiency of this
vitamin in CAPD patients [10, 41, 43—46]; however, Boeschoten
et al [47] found that 2 mg/day was sufficient to obtain normal
blood concentrations of vitamin B6 in their CAPD patients. In
addition, taurine depletion in uremia may to some extent be a
consequence of increased hepatic elimination after conjugation
with bile acids [41, 48]. The daily taurine loss into the dialysate
during CAPD is less than 100 mg; in fact, the molar dialysate/
plasma ratio for taurine appears to be lower than for most other
amino acids [7—10]. Compared with the very high intracellular
content of taurine in muscle, these losses are probably insignif-
icant.
Nutritional requirements for taurine in man are largely un-
known. However, children and, possibly, adults receiving
long-term parenteral nutrition, have been reported to develop
low plasma taurine levels and signs of taurine depletion with
abnormalities of the electroretinogram, which are reversed after
taurine supplementation [49, 50]. Taurine seems to have a
functional role in membranes, calcium flux, and possibly cyclic
AMP activity, and is involved in a wide range of metabolic
responses in the central nervous system, in the retina, and in
the heart [41, 49, 51—53]. The consequences of reduced extra-
and intracellular taurine pools in the CAPD pools are not
known, although one may speculate whether this alteration
might contribute to impaired blood glucose control [41], cardio-
vascular disease [53, 54], and neurological disorders [41].
In summary, the results of the present study suggest that
except for taurine, the intracellular free amino acid pattern in
muscle is less abnormal in CAPD patients than in uremic
patients undergoing forms of therapy. By contrast, the plasma
levels of most of the essential and several non-essential amino
acids appear to be lower in CAPD patients than in other
categories of uremic patients. The grossly abnormal plasma
amino acid pattern in the CAPD patients may not necessarily be
a consequence of amino acid depletion, but rather reflect an
increased transport of amino acids across the cell membrane,
possibly because of the sustained hyperinsulinemia during
CAPD treatment, resulting in an increased ic/cc gradient. The
finding of low intra- and extracellular pools of taurine in the
presence of high or normal concentrations of the taunne pre-
cursors methionine and cysteine suggests that this deficiency
might be caused by blocked synthesis of taurine, perhaps
combined with inadequate intake and increased hepatic elimi-
nation of taurine.
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